PMID: 9191523Jun 15, 1997Paper

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

Cancer
L RuscianiG Vezzoni

Abstract

Early surgical intervention is still the most successful therapy for patients with melanoma. The results obtained with medical therapies are still quite disappointing, with better results observed in soft tissue and lymph node metastasis. There currently is no standardized adjuvant therapy for primary melanoma. On the basis of the activity demonstrated in vitro against melanoma cell lines and the results obtained in many clinical trials in patients with advanced melanoma, the authors chose to study the use of recombinant interferon-alpha (IFN-alpha) as adjuvant therapy for patients with Stage I and Stage II melanoma. A randomized multicenter trial based on the use of recombinant IFN-alpha-2b for 3 years at the dose of 3 MU given intramuscularly 3 times a week for a period of 6 months with a 1-month interval between cycles was conducted in Stage I and Stage II melanoma patients (using the American Joint Committee on Cancer classification). The efficacy of this treatment was evaluated calculating the incidence of recurrence after 3 and 5 years. Results were collected at the end of the treatment period and after 5 years of follow-up for a smaller number of patients. Statistical evaluation showed a significant difference between tr...Continue Reading

References

Dec 1, 1990·The Journal of Investigative Dermatology·J M Kirkwood, M S Ernstoff
Dec 1, 1990·The Journal of Investigative Dermatology·G R McLeodP Hersey
Jul 18, 1991·The New England Journal of Medicine·H K Koh
Jun 1, 1991·Journal of the American Academy of Dermatology·T A Luger, T Schwarz
Feb 1, 1990·Journal of the American Academy of Dermatology·V C Ho, A J Sober
Sep 1, 1990·Journal of the American Academy of Dermatology·R P GallagherL M Warshawski
Dec 1, 1990·The Journal of Investigative Dermatology·E M KokoschkaM Micksche
Oct 1, 1989·Photochemistry and Photobiology·N Cascinelli, R Marchesini
Feb 1, 1983·Cancer·H TrauW R Grier
Jul 1, 1995·British Medical Bulletin·R M MacKie
Jul 1, 1995·Annals of Surgical Oncology·S S Agarwala, J M Kirkwood
Jan 1, 1995·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·K KrasagakisC E Orfanos
Mar 29, 1995·International Journal of Cancer. Journal International Du Cancer·J Rodríguez-Villanueva, T J McDonnell
May 1, 1995·Journal of the American Academy of Dermatology·T M JohnsonA Chang
Jan 15, 1995·Cancer·A Barth, D L Morton
Aug 1, 1994·International Journal of Epidemiology·M BerwickJ Flannery
May 1, 1994·Cancer·E Månsson-BrahmeL E Rutqvist
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S Aapro
Jan 1, 1995·Dermatology : International Journal for Clinical and Investigative Dermatology·G C DoveilM G Bernengo
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum

❮ Previous
Next ❯

Citations

Jul 20, 1999·The Annals of Pharmacotherapy·E Durán GarcíaT Requena
Aug 10, 1999·International Journal of Dermatology·K J Smith, H Skelton
Aug 24, 1999·Annals of Surgical Oncology·K M McMastersM I Ross
Jun 12, 2002·Current Treatment Options in Oncology·V K SondakL M Schuchter
Sep 5, 2002·Cancer·Vernon K Sondak
Apr 30, 2003·Current Treatment Options in Oncology·Alicia TerandoVernon K Sondak
Feb 7, 2019·Cancer Immunology, Immunotherapy : CII·Lorena P Suarez-KellyWilliam E Carson
Apr 12, 2000·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·C C Otley, J A Zitelli
Oct 8, 2003·The Oncologist·Michael S Sabel, Vernon K Sondak
Jun 19, 2013·The Cochrane Database of Systematic Reviews·Simone MocellinVanna Chiarion Sileni
Jul 25, 2018·American Journal of Clinical Dermatology·Meredith A McKean, Rodabe N Amaria
Feb 25, 2010·Journal of the National Cancer Institute·Simone MocellinDonato Nitti
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Aug 17, 2005·Cancer Investigation·Saji Eapen, Janice P Dutcher
Jan 20, 2021·Head & Neck·Ryan P GoepfertJeffrey E Gershenwald
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marko B Lens, Martin Dawes
May 31, 2020·Cancer Treatment Reviews·Tara D BaetzTeresa M Petrella
Jan 31, 2006·Journal of the American Academy of Dermatology·Luigi RuscianiSilvio Lippa
Apr 15, 2006·World Journal of Surgical Oncology·Gianlorenzo DionigiRenzo Dionigi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.